Regular Article
Prediction of Human Disposition toward S-3H-Warfarin using Chimeric Mice with Humanized Liver

https://doi.org/10.2133/dmpk.24.153Get rights and content

Summary:

Chimeric mice, constructed by transplanting human hepatocytes, are useful for predicting the human metabolism of drug candidates. In this study, we investigated whether these mice show similar metabolic profile to humans by examining the hydroxylation of S-warfarin reported to be mainly metabolized to S-7- hydroxywarfarin (7-OH-warfarin), catalyzed by CYP2C9, in humans. When S-3H-warfarin was administered to chimeric mice and control (uPA + / + /SCIDwt/wt) mice, the blood concentration-time curve was higher in chimeric than control mice. Plasma protein binding of S-3H-warfarin of chimeric and control mice amounted to 98.1 and 92.1%, respectively. When S-3H-warfarin was administered to these mice, radioactivity was mainly recovered in urine (81.7% in chimeric mice and 65.9% in control mice). After S-3H-warfarin was administered to these mice, the radioactivity was recovered in the bile of chimeric and control mice at 5.1 and 17.9%, respectively. The main urinary metabolite in chimeric mice was 7-OH-warfarin. the main urinary metabolite in control mice was S-4'-hydroxywarfarin. These results show that mass balance, metabolic disposition of S-3H-warfarin in chimeric mice with humanized liver were similar to reported human data.

References (40)

  • Q. Zhou et al.

    Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats

    Eur. J. Pharm. Sci.

    (2003)
  • R.J. Lewis et al.

    Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols

    J. Lab. Clin. Med.

    (1973)
  • H.G. Shetty et al.

    Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy

    Clin. Pharmacokinet.

    (1989)
  • H. Takahashi et al.

    Pharmacogenetics of warfarin elimination and its clinical implications

    Clin. Pharmacokinet.

    (2001)
  • R.A. O'Reilly

    Studies on the optical enantiomorphs of warfarin in man

    Clin. Pharmacol. Ther.

    (1794)
  • E. Chan et al.

    Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfa rin

    Br. J. Clin. Pharmacol.

    (1994)
  • L.S. Kaminsky et al.

    Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe

    Mol. Pharmacol.

    (1993)
  • A.E. Rettie et al.

    Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

    Chem. Res. Toxicol.

    (1992)
  • A.E. Rettie et al.

    Characteristics of warfarin hydroxylation catalyzed by human liver microsomes

    Drug Metab. Dispos.

    (1989)
  • D.J. Black et al.

    Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

    Drug Metab. Dispos.

    (1996)
  • Cited by (34)

    • Genetically Humanized Animal Models

      2017, Comprehensive Medicinal Chemistry III
    • Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients

      2015, Journal of Cardiology
      Citation Excerpt :

      Recently, a growing body of evidence suggests that the pharmacokinetics and pharmacodynamics of drugs that are eliminated primarily by metabolic processes in the liver are also altered by compromised renal function, leading to significant reductions in nonrenal clearance of such drugs [1–4]. Warfarin is eliminated through hepatic metabolism and not directly excreted by the kidney [5–8]. However, when treated with warfarin, patients with chronic renal impairment have higher risk of both hemorrhagic [29–33] and ischemic [34,35] events than those with normal renal function.

    • Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice

      2012, Phytomedicine
      Citation Excerpt :

      This may also have contributed to the unclear influence of bilobalide on (S)-warfarin concentration. Species differences exist in warfarin metabolism; (S)-warfarin is mainly metabolized to (S)-7-hydroxywarfarin in humans and to (S)-4-hydroxywarfarin with some (S)-7-hydroxywarfarin in mice (Inoue et al. 2009). In the present study, it is difficult to extrapolate the findings to how GBE and bilobalide influence the pharmacokinetics of warfarin in humans.

    View all citing articles on Scopus
    View full text